TY -的T1中断6个月治疗后的复发时间频率和静脉注射免疫球蛋白或甲基强的松龙在慢性炎性脱髓鞘多神经根神经病(P7.002) JF -神经学乔-神经学六世- 82 - 10补充SP - P7.002 AU -爱德华多Nobile-Orazio AU -达里奥Cocito AU -斯特凡诺Jann盟Antonino Uncini AU -保罗·梅西纳盟埃托雷Beghi AU -乔瓦尼Antonini盟Raffaella首页法齐奥盟-弗朗西斯卡高卢盟安吉洛Schenone AU - Ada地区非盟-大卫。Pareyson盟卢西奥澳网AU -斯特凡诺Tamburin盟Guido Cavaletti AU -法比奥Giannini盟马里奥Sabatelli Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/P7.002.abstract N2 -目标。比较中断持续治疗后复发的频率和时间与静脉注射免疫球蛋白(丙种球蛋白)或甲基强的松龙(IVMP)患者的慢性炎性脱髓鞘多神经根神经病(CIDP)。背景。我们最近报道说,6个月更频繁了用丙种球蛋白治疗有效或容忍比甲基强的松龙(IVMP) CIDP患者。然而更多的病人恶化,需要比IVMP中断治疗后的六个月的丙种球蛋白。我们延长了后续比较患者的比例最终治疗停药后复发。方法。截至2013年3月,数据可以从41的45患者完成试验平均随访治疗停药后42个月(范围1-60)三个病人已经退休在最初的研究和一个未能应对两个治疗方法。没有病人接受诊断在后续CIDP的替代品。结果。 Twenty-eight of the 32 patients treated with IVIg as primary or secondary therapy after failing to respond to IVMP improved after therapy (87.5%) as compared to 13 of the 24 patients treated with IVMP as primary or secondary therapy (54.2%). After a median follow-up of 42 months (range 1-57), 24 out of 28 patients responsive to IVIg (85.7%) worsened after therapy discontinuation. The same occurred to 10 out of 13 patients (76.9%) treated with IVMP (p: 0.659) after a median follow-up of 43 months (range 7-60). Worsening occurred 1-24 months (median 4.5) after IVIg discontinuation and 1-31 months (median 14) after IVMP discontinuation (p: 0.0126). Kaplan-Meier survival curves of the between groups time to relapse censored at 1, 2 and 3 years of follow-up reported log-rank p-values of 0.0139, 0.0272 and 0.0278. CONCLUSIONS. A similarly high proportion of patients treated with IVIg or IVMP eventually relapse after therapy discontinuation but the median time to relapse is significantly longer after IVMP than IVIg. These results may influence the initial choice of treatment in CIDP. Disclosure: Dr. Nobile-Orazio has received personal compensation for activities with CSL Behring, Baxter Laboratories, and Novartis. Dr. Cocito has received personal compensation for activities with Baxter, and CSL Behring. Dr. Jann has received personal compensation for activities with Eli Lilly & Co., BioFutura Pharma, Abbott, and Kedrion. Dr. Uncini has nothing to disclose. Dr. Messina has nothing to disclose. Dr. Beghi has received personal compensation for activities with GlaxoSmithKlyne Inc., UCB Pharma, and Viropharma. Dr. Beghi has received personal compensation in an editorial capacity for Epilepsia. Dr. Beghi has received research support from UCB Pharma and GlaxoSmithKlyne Inc. Dr. Antonini has nothing to disclose. Dr. Fazio has received personal compensation for activities with Baxter. Dr. Gallia has nothing to disclose. Dr. Schenone has nothing to disclose. Dr. Francia has nothing to disclose. Dr. Pareyson has nothing to disclose. Dr. Santoro has nothing to disclose. Dr. Tamburin has nothing to disclose. Dr. Cavaletti has nothing to disclose. Dr. Giannini has nothing to disclose. Dr. Sabatelli has nothing to disclose.Thursday, May 1 2014, 3:00 pm-6:30 pm ER -